Anthem officials told a judge on Monday that their counterparts at Cigna sabotaged the $48.9 billion merger deal, even refusing to divest business lines that would have won them approval by regulators.
Fresenius Medical Care announced Tuesday it has completed the $2 billion purchase of home dialysis devicemaker NxStage Medical.
The U.S. Justice Department asked a judge on Monday to formally approve the merger between CVS Health and insurer Aetna.
The Children's Hospital of Philadelphia Foundation is about to see a more than $450 million windfall from its ownership stake in a spinout drug company that is being purchased by Roche in a deal worth nearly $5 billion.
Members of Modern Healthcare's CEO Power Panel say the allure of mergers and acquisitions may be losing its stronghold over health system leaders. Finances may slide in 2019, but CEOs insist it's for good reason.
Centene Corp. CEO Michael Neidorff says the large Medicaid managed-care plan is well positioned to deliver high quality products that lower costs.
DaVita reported net income of $159 million in 2018, down from $664 million in 2017. The company's CEO assured the audience on a call Thursday that the sale of DaVita Medical Group to UnitedHealth Group will close soon.
The proposed merger of Partners HealthCare and Care New England won't have a dramatic effect on Massachusetts healthcare spending, even if care patterns significantly change, according to the Massachusetts Health Policy Commission.
Private equity firms Veritas Capital and Evergreen Coast Capital have closed on their $5.7 billion purchase of Athenahealth, which will be combined with Virence Health Technologies under the Athenahealth name and brand.
The Renton, Wash.-based integrated healthcare system acquired Lumedic, which aims to inject efficiency and interoperability into what are often archaic systems of collecting, analyzing and distributing claims and billing.
Athenahealth's shareholders have given the green light for the EHR vendor to be purchased by two private equity firms in a deal worth $5.7 billion. They also supported a generous compensation package for the company's executive officers and directors.
While executives didn't outline why the deal fell through, there had been some concern regarding the alignment of their academic missions as well as a mismatch of their physician-management models, sources close to the matter said.